Pharmafile Logo

Understanding Patient Willingness to Pay

January 6, 2016 | emerging markets 

Published in eyeforpharma 12 October by Rachel Howard

What steps should pharma and medical device companies take to ensure they get their pricing strategy right in self-pay markets?

A key feature of emerging markets is that patients often have to self-fund a high proportion of their healthcare costs. For all but the most severe conditions, public reimbursement of pharmaceutical products and personal medical devices is often partial to non-existent, particularly in the outpatient setting. While private health insurance coverage is increasing in many emerging markets, penetration typically remains low, even among middle to high income segments of the population. This means that for many drugs and devices, the primary means of purchasing in emerging markets will be patients paying out of pocket. Any successful pricing strategy therefore needs to start with an understanding of target patients’ willingness to pay for the drug / device in question.

In this article, I partner with Research Partnership Quantitative Director and pricing expert Duncan Munro to set out the critical success factors that should be considered in order to determine how a medical product should be priced in a self-pay market.

Read the full article here:
www.researchpartnership.com/news/2015/10/article-understanding-patient-willingness-to-pay/


This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Event: Richard Head presented with MR Excellence award at EphMRA Conference

Research Partnership were delighted to exhibit, sponsor and present three papers at the EphMRA conference where Director Richard Head was presented with one of this year's MR Excellence Awards.Find out...

How patient insights were brought to life with graphic novel outputs

Research Partnership's client was developing a novel therapy for the treatment of a rare disease in which patients suffer acute symptomatic attacks; the main burden of disease is not just...

Research Partnership publishes new patient Living with Ankylosing Spondylitis & nr-axSpA EU & US 2019 reports

Living with Ankylosing Spondylitis (AS) & nr-AxSpA are reports based on quantitative studies conducted online in the 5EU and US. The AS 5EU report comprises of interviews with 385 patients...

Webinar: Usability and UX: You’ve been asked to test…What next?

Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST

Event: EphMRA Annual Conference

We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland.

Research Partnership and Janssen awarded runner-up in MR Excellence Awards

We are delighted to announce that an entry by Janssen and Research Partnership for the 2019 EphMRA MR Excellence Awards has been awarded runner-up in the ‘Business Impact through Innovation’...

Infographic: The vaccine opportunity in Asia

Asia is home to 60% of the world’s population and is one of the fastest growing vaccine markets in the world. A rising demand for better healthcare infrastructure and high...

Event: World Pharma Pricing and Market Access Congress

Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March.This two-day event was attended by over 600 delegates, including a number...

Event: Intellus Worldwide Summit 2019

Visit us on stand number 311

Blog: The Future of Food Allergy? The Emergence of Targeted Allergy Treatments

Research Analyst Rachel Arthurs explores how public exposure to the complications of food allergy has affected attitudes toward treatment.In recent years, there has been a noticeable shift in the increased...